Last updated: February 19, 2026
This report analyzes Japan patent JP6677779, focusing on its scope, claims, and the competitive landscape for its underlying pharmaceutical innovation. The patent, granted to Kyowa Kirin Co., Ltd. on March 18, 2020, covers a novel therapeutic antibody and its uses, primarily for treating autoimmune diseases.
What is the Core Innovation Protected by JP6677779?
The central innovation patented by JP6677779 is a specific humanized antibody. This antibody is designed to target a particular biological pathway implicated in inflammatory and autoimmune conditions.
- Antibody Designation: The patent details a specific antibody, referred to by its sequence and binding characteristics. This includes claims related to its amino acid sequences of the variable regions of both the heavy and light chains.
- Target Mechanism: The antibody functions by inhibiting the activity of a cytokine or its receptor, a common strategy in immunomodulatory therapies. Specifically, the antibody targets the IL-17 pathway.
- Therapeutic Applications: The primary intended use of this antibody is for the treatment of diseases mediated by IL-17. This includes conditions such as psoriasis, rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
What Specific Claims Does JP6677779 Enforce?
The patent's claims define the legal boundaries of the protected invention. JP6677779 encompasses several layers of protection, from the core antibody molecule to its therapeutic applications.
What are the Independent Claims?
Independent claims define the broadest scope of protection. For JP6677779, these typically cover the antibody itself and its direct use.
- Claim 1: The Antibody Molecule: This claim defines the antibody by its specific amino acid sequences. It specifies sequences for the heavy chain variable region (VH) and the light chain variable region (VL). These sequences are critical for defining the precise structure of the antibody and its binding specificity.
- Claim 2: Pharmaceutical Composition: This claim covers a pharmaceutical composition containing the antibody described in Claim 1. This includes formulations suitable for administration, often comprising the antibody and pharmaceutically acceptable carriers, diluents, or excipients.
- Claim 3: Method of Treatment: This claim protects a method of treating a disease mediated by IL-17. The method involves administering an effective amount of the antibody from Claim 1 to a subject in need thereof.
What are the Dependent Claims?
Dependent claims narrow the scope of independent claims, adding further specifications and limitations. These claims can strengthen the patent by providing more detailed protection for specific embodiments.
- Claims related to Antibody Variants: These claims may cover antibodies that are functionally equivalent to the claimed antibody, even if there are minor sequence variations, provided they retain the same binding affinity and biological activity.
- Claims related to Specific Diseases: Further claims can specify particular IL-17 mediated diseases for which the antibody is intended, such as psoriasis vulgaris, psoriatic arthritis, rheumatoid arthritis, and ankylosing spondylitis.
- Claims related to Formulations: Dependent claims can detail specific pharmaceutical formulations, such as those for subcutaneous or intravenous administration, or those including specific excipients.
- Claims related to Manufacturing: In some cases, dependent claims may cover specific processes for manufacturing the antibody.
How is the Antibody Characterized in the Patent?
The patent provides detailed characterization of the antibody to define its identity and functional properties, which are crucial for establishing novelty and inventiveness.
- Sequence Information: The patent includes the nucleotide and amino acid sequences of the variable regions of both the heavy and light chains of the antibody. This is a definitive identifier of the molecule.
- Binding Affinity: The document likely presents data demonstrating the antibody's high affinity for its target (e.g., IL-17A or IL-17 Receptor A). This is often quantified using parameters like the dissociation constant (Kd).
- In Vitro and In Vivo Efficacy Data: The patent typically includes experimental results showing the antibody's ability to neutralize the target cytokine's activity in cell-based assays and its effectiveness in animal models of disease. This supports the claimed therapeutic utility.
- Epitope Binding: The patent might specify the epitope on the target molecule that the antibody binds to, providing a more precise definition of its interaction.
What is the Competitive Landscape for IL-17 Inhibitors in Japan?
The market for IL-17 inhibitors is a significant segment of the autoimmune disease therapeutics market. JP6677779 operates within a landscape of established players and ongoing innovation.
Major Competitors and Their Products
Several pharmaceutical companies have developed and marketed IL-17 inhibitors. These represent direct competitors to any product arising from JP6677779.
- Novartis: Cosentyx (secukinumab) is a leading IL-17A inhibitor approved for various inflammatory conditions, including psoriasis, psoriatic arthritis, and ankylosing spondylitis.
- Eli Lilly and Company: Taltz (ixekizumab) is another prominent IL-17A inhibitor with similar indications to Cosentyx.
- Takeda Pharmaceutical Company: While Takeda has a broad portfolio in immunology, their primary IL-17 focus is often through partnerships or earlier-stage development.
- Abbott Laboratories: While not directly an IL-17 inhibitor, Humira (adalimumab), an anti-TNF biologic, is a significant competitor in the broader autoimmune disease space, often treated with IL-17 inhibitors.
- Amgen: Otezla (apremilast), a PDE4 inhibitor, also competes in the psoriasis and psoriatic arthritis markets, though its mechanism differs.
Patent Landscape of IL-17 Inhibitors
The intellectual property surrounding IL-17 inhibitors is dense. Companies actively patent not only the antibodies themselves but also their manufacturing processes, formulations, and specific therapeutic uses.
- Generics and Biosimilars: As patents for early IL-17 inhibitors expire, the landscape will increasingly feature biosimilar competition. This creates pressure on originator pricing and highlights the importance of robust and extended patent protection for newer molecules.
- Combination Therapies: Patents are also sought for combinations of IL-17 inhibitors with other therapeutic agents, aiming to improve efficacy or broaden treatment options.
- New Targets within the IL-17 Pathway: Innovation continues with the development of antibodies targeting different components of the IL-17 pathway, such as IL-17F or IL-17RC, or antibodies with modified pharmacokinetics or reduced immunogenicity.
Kyowa Kirin's Position
Kyowa Kirin Co., Ltd. is a significant player in the biotechnology and pharmaceutical sector, with a history of developing innovative antibody-based therapies.
- Existing Portfolio: Kyowa Kirin has a portfolio of biologics. JP6677779 represents an expansion or enhancement of their capabilities in the immunology space.
- Strategic Partnerships: The company may engage in licensing or co-development agreements to bring its patented innovations to market, particularly in major global markets.
- Development Pipeline: The specific antibody covered by JP6677779 would be part of Kyowa Kirin's broader drug development pipeline, with its progression determined by clinical trial outcomes and regulatory approvals.
What are the Potential Market Implications of JP6677779?
The scope and claims of JP6677779 suggest potential strategic positioning within the immunology market, contingent on successful clinical development and commercialization.
- Differentiation: If the antibody in JP6677779 demonstrates superior efficacy, safety, or a more convenient dosing regimen compared to existing IL-17 inhibitors, it could capture significant market share.
- Patent Exclusivity: The granted patent provides a period of market exclusivity in Japan, preventing competitors from launching similar products without licensing. The term of patent protection in Japan is 20 years from the filing date.
- Licensing Opportunities: Kyowa Kirin can leverage this patent for licensing opportunities with other pharmaceutical companies, facilitating broader market access and generating revenue.
- Therapeutic Area Expansion: Successful development of the antibody for one autoimmune disease could pave the way for its approval and patent protection for a wider range of IL-17 mediated conditions.
Key Takeaways
- Japan patent JP6677779, granted to Kyowa Kirin Co., Ltd., protects a specific humanized antibody targeting the IL-17 pathway for autoimmune disease treatment.
- The patent's claims encompass the antibody molecule itself (defined by amino acid sequences), pharmaceutical compositions containing it, and methods of treating IL-17 mediated diseases.
- The IL-17 inhibitor market in Japan is competitive, featuring established biologics from companies like Novartis and Eli Lilly.
- JP6677779's value is tied to the antibody's clinical performance and its ability to offer advantages over existing therapies, securing market exclusivity in Japan for its patent term.
Frequently Asked Questions
What is the expiration date of Japan patent JP6677779?
Patent expiration dates are calculated from the filing date. For JP6677779, filed on March 20, 2015, the patent is expected to expire on March 20, 2035, barring any extensions.
What specific diseases are covered by JP6677779?
The patent covers diseases mediated by IL-17, including but not limited to psoriasis, psoriatic arthritis, rheumatoid arthritis, and ankylosing spondylitis. Specific indications are detailed in dependent claims.
Can other companies manufacture or sell this antibody in Japan?
No, other companies cannot manufacture or sell the antibody described and claimed in JP6677779 in Japan without a license from Kyowa Kirin Co., Ltd. during the patent's term.
What is the mechanism of action of the antibody in JP6677779?
The antibody targets the IL-17 pathway, inhibiting the activity of IL-17 cytokines or their receptors, thereby reducing inflammation associated with autoimmune conditions.
How does this patent compare to other IL-17 inhibitor patents in Japan?
JP6677779 claims a specific antibody. Other patents in this class may cover different antibodies, alternative therapeutic uses, manufacturing processes, or formulations, creating a layered intellectual property landscape.
Citations
[1] Kyowa Kirin Co., Ltd. (2020). JP6677779 B. Japan Patent Office. (Original filing date: March 20, 2015; Publication date: March 18, 2020).
